Objective:

To develop a lymphoma-specific nomogram for predicting venous thromboembolism (TE) risk in lymphoma patients, enhancing clinical decision-making.

Key Findings:

• 9.75% of patients developed thromboembolism, with higher rates in non-Hodgkin lymphoma (10.5%) compared to Hodgkin lymphoma (4.6%), indicating a need for targeted risk assessment.
• The median time from chemotherapy initiation to TE diagnosis was 4 months, highlighting the critical period for monitoring.
• Upper-limb venous thrombosis was the most common type, with deep-vein thrombosis being predominant, suggesting specific areas for clinical focus.

Interpretation:

The study highlights the need for lymphoma-specific risk assessment tools to improve the identification and management of patients at high risk for thromboembolism, potentially leading to better patient outcomes.

Limitations:

• Retrospective design may introduce bias, such as selection bias and information bias.
• Findings may not be generalizable to all lymphoma populations, particularly those outside the study's demographic.

Conclusion:

A lymphoma-specific nomogram was developed to aid in the prediction of venous thromboembolism risk, emphasizing the importance of tailored approaches in managing cancer-associated complications and the need for future validation studies.